Short Interest in HCW Biologics Inc. (NASDAQ:HCWB) Drops By 67.5%

HCW Biologics Inc. (NASDAQ:HCWB) saw a large decrease in short interest in October. As of October 31st, there was short interest totalling 8,100 shares, a decrease of 67.5% from the October 15th total of 24,900 shares. Based on an average daily trading volume, of 27,600 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.0% of the company’s shares are sold short.

HCW Biologics Trading Down 12.3 %

NASDAQ:HCWB traded down $0.04 on Tuesday, reaching $0.32. The company’s stock had a trading volume of 1,241,993 shares, compared to its average volume of 25,830. HCW Biologics has a 12-month low of $0.30 and a 12-month high of $1.93. The firm has a market cap of $11.95 million, a price-to-earnings ratio of -0.35 and a beta of 0.83. The stock has a 50 day moving average price of $0.51 and a 200 day moving average price of $0.72. The company has a quick ratio of 0.10, a current ratio of 0.10 and a debt-to-equity ratio of 0.95.

HCW Biologics (NASDAQ:HCWB) last posted its earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share for the quarter. HCW Biologics had a negative net margin of 978.03% and a negative return on equity of 385.90%. The company had revenue of $0.62 million during the quarter.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.